GLPwatch
Papers (9189)
Page 110 of 154, ranked by citation count.
- Combination of exendin-4 and DPP-4 silencing promoted angiogenesis of human coronary artery endothelial cells via activation of PI3K/Akt pathway.
- Effect of fixed-dose combination of insulin degludec and liraglutide on apoB-containing lipoprotein subclasses and HDL lipidome in type 2 diabetes.
- Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: <i>post-hoc</i> analysis of the SURMOUNT-5 trial.
- Clinical Efficacy and Safety of Liraglutide and Dapagliflozin on Glucose and Lipid Metabolism and Insulin Function in Patients with Type 2 Diabetes Mellitus.
- Gut microbiota mediates semaglutide attenuation of diabetes-associated cognitive decline.
- Liraglutide (Victoza) for type 2 diabetes.
- Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.
- HOMA-S is associated with greater HbA1c reduction with a GLP-1 analogue in patients with type 2 diabetes.
- Safety and Efficacy of Liraglutide and Semaglutide in Kidney Transplant Recipients.
- Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4.
- Retatrutide-A Game Changer in Obesity Pharmacotherapy.
- Once-Weekly Semaglutide in Adolescents with Obesity.
- Activation of the HPA Axis Does Not Explain Nonresponsiveness to GLP-1R Agonist Treatment in Individuals With Type 2 Diabetes.
- Treatment of Type 2 Diabetes in Patients with Obesity: A Review.
- Exenatide ER-induced eosinophilia.
- Weighing in on glucagon-like peptide-1 receptor agonists in dermatology.
- An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review.
- Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.
- Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.
- Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies.
- Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus.
- Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions.
- Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome.
- Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.
- Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus.
- Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial.
- Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.
- Point-of-Care Ultrasound Aids in the Management of Patient Taking Semaglutide Before Surgery: A Case Report.
- Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus.
- Chemical chaperone-conjugated exendin-4 as a cytoprotective agent for pancreatic β-cells.
- Combined effects of voluntary running and liraglutide on glucose homeostasis, fatty acid composition of brown adipose tissue phospholipids, and white adipose tissue browning in db/db mice.
- GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential.
- The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model.
- Treat to target in weight management with semaglutide: Real-world evidence from an eHealth clinic.
- Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk.
- A Revolution in the Treatment of Obesity.
- Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
- Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting.
- Beyond Diabetes: Semaglutide's Role in Modulating Mood Disorders through Neuroinflammation Pathways.
- Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome.
- A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk - Study rationale and design.
- Preparation and evaluation of lactic acid acylated exenatide and its long-acting preparation.
- Improvement of liraglutide release from PLGA microspheres by a porous microsphere-gel composite system.
- Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience.
- Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations.
- Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes.
- Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control.
- Tirzepatide Trial Demonstrates Substantial Weight Loss.
- Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
- What Does the Rise of GLP-1 Drugs Mean for Bariatric Surgery?
- Patients Are Flocking to Compounded Weight-Loss Drugs, but Are They Safe?
- Glucagon-Like Peptide-1 Use and Healthcare Resource Utilization for Depression and Anxiety Among Adults with Type 2 Diabetes: 2019 to 2023.
- Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.
- Obesity update: cardiovascular risk and therapeutic innovations (focus on semaglutide and tirzepatide).
- Tirzepatide vs. Semaglutide for Obesity Treatment. Reply.
- Semaglutide and Tirzepatide to Treat Obesity.
- Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.
- Liraglutide Attenuates FFA-Induced Retinal Pigment Epithelium Dysfunction via AMPK Activation and Lipid Homeostasis Regulation in ARPE-19 Cells.
- Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study.
- A single-center study on the biochemical effect and clinical effectiveness of liraglutide in Turkish patients.